Pharma BD Deal Intelligence

Lantheus Holdings, Inc. / Life Molecular Imaging Ltd.

2025 · Acquisition/Merger · $750M · Pending

Lantheus announced a definitive agreement on January 13, 2025 to acquire Life Molecular Imaging Ltd., a subsidiary of Life Healthcare Group Holdings, for an upfront payment of $350.0 million plus up to $400.0 million in earn-out and milestone payments. The acquisition adds Neuraceq, an approved PET radiodiagnostic for beta-amyloid imaging, establishing a Lantheus commercial franchise in Alzheimer's disease. Both boards unanimously approved; closing was expected in the second half of 2025 subject to regulatory approvals. Status recorded as of announcement.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals